GUARNERI, VALENTINA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 27.457
AS - Asia 18.183
EU - Europa 9.118
AF - Africa 3.164
SA - Sud America 2.975
Continente sconosciuto - Info sul continente non disponibili 640
OC - Oceania 273
Totale 61.810
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 25.459
SG - Singapore 5.268
CN - Cina 2.947
VN - Vietnam 2.598
IT - Italia 2.464
HK - Hong Kong 1.892
BR - Brasile 1.781
BD - Bangladesh 1.105
DE - Germania 865
FI - Finlandia 829
FR - Francia 682
IN - India 660
CA - Canada 408
PL - Polonia 399
SE - Svezia 369
GB - Regno Unito 348
NL - Olanda 337
RU - Federazione Russa 297
AR - Argentina 287
IQ - Iraq 287
TR - Turchia 286
JP - Giappone 222
ID - Indonesia 207
PH - Filippine 206
SA - Arabia Saudita 184
MX - Messico 180
ZA - Sudafrica 166
PK - Pakistan 160
ES - Italia 157
AT - Austria 153
BJ - Benin 148
EC - Ecuador 144
KR - Corea 132
TN - Tunisia 132
CO - Colombia 130
IE - Irlanda 126
UA - Ucraina 126
UZ - Uzbekistan 119
CL - Cile 116
JO - Giordania 115
CI - Costa d'Avorio 112
MY - Malesia 110
PE - Perù 107
KE - Kenya 106
PS - Palestinian Territory 106
AE - Emirati Arabi Uniti 105
HU - Ungheria 104
MA - Marocco 103
NP - Nepal 102
AZ - Azerbaigian 100
HN - Honduras 99
IL - Israele 98
JM - Giamaica 97
VE - Venezuela 97
BE - Belgio 96
EG - Egitto 96
MK - Macedonia 96
AO - Angola 95
GT - Guatemala 95
CR - Costa Rica 94
RS - Serbia 94
LB - Libano 90
CZ - Repubblica Ceca 89
PA - Panama 88
TH - Thailandia 88
BA - Bosnia-Erzegovina 87
CH - Svizzera 86
NO - Norvegia 85
PR - Porto Rico 85
DO - Repubblica Dominicana 84
PY - Paraguay 84
ET - Etiopia 83
LC - Santa Lucia 83
LV - Lettonia 83
NI - Nicaragua 83
BG - Bulgaria 82
BO - Bolivia 82
HR - Croazia 82
LY - Libia 79
ME - Montenegro 78
SI - Slovenia 78
TT - Trinidad e Tobago 78
TW - Taiwan 78
AL - Albania 77
GH - Ghana 77
CY - Cipro 76
BB - Barbados 75
MD - Moldavia 75
MZ - Mozambico 75
SN - Senegal 75
DZ - Algeria 74
IR - Iran 74
MG - Madagascar 74
ML - Mali 74
PT - Portogallo 74
UY - Uruguay 74
BY - Bielorussia 73
CM - Camerun 72
EE - Estonia 72
GR - Grecia 72
Totale 57.701
Salva come PNG Salva come JPEG
Città #
Ashburn 3.525
Singapore 3.163
Fairfield 2.654
San Jose 2.593
Hong Kong 1.681
Woodbridge 1.466
Houston 1.369
Chandler 1.098
Ann Arbor 979
Seattle 914
Cambridge 887
Wilmington 799
Ho Chi Minh City 792
Santa Clara 654
Los Angeles 607
Hanoi 585
Helsinki 519
Boardman 512
Munich 494
Beijing 477
New York 428
Lauterbourg 313
San Diego 278
Princeton 266
Padova 260
Bytom 255
Milan 252
Medford 251
Council Bluffs 231
Buffalo 219
Chicago 218
Des Moines 218
São Paulo 183
Rome 177
Da Nang 155
Hefei 152
Cotonou 138
Dallas 137
Tokyo 134
Nanjing 124
Guangzhou 120
Padua 118
Baghdad 117
Roxbury 109
Abidjan 107
Amman 104
Haiphong 104
Tashkent 103
Dong Ket 102
London 101
Dublin 97
Pune 95
Frankfurt am Main 91
Montreal 90
Baku 88
Orem 87
Nairobi 85
Nuremberg 84
Castries 81
Panama City 79
Vienna 79
Warsaw 78
Managua 77
Chennai 75
Luanda 75
San José 75
Turku 75
Toronto 74
Brooklyn 73
Naples 73
Dakar 72
Podgorica 72
Addis Ababa 69
Amsterdam 69
Bridgetown 69
Antananarivo 68
Lusaka 68
Conakry 67
Istanbul 67
Johannesburg 67
Accra 66
Jeddah 66
Riyadh 66
Kampala 65
Nassau 65
Riga 64
Salt Lake City 64
Bamako 63
Dushanbe 63
Harare 62
Phnom Penh 62
Atlanta 61
Havana 61
Seoul 61
Montevideo 60
Redondo Beach 60
Guatemala City 59
Kigali 58
Libreville 58
Nouakchott 58
Totale 34.803
Salva come PNG Salva come JPEG
Nome #
Combined Immunoscore for Prognostic Stratification of Early Stage Non-Small-Cell Lung Cancer 546
ESR1 Gene Mutation in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer Patients: Concordance Between Tumor Tissue and Circulating Tumor DNA Analysis 386
From Diagnostic-Therapeutic Pathways to Real-World Data: A Multicenter Prospective Study on Upfront Treatment for EGFR-Positive Non-Small Cell Lung Cancer (MOST Study) 366
Chemotherapy for advanced HER2-negative breast cancer: Can one algorithm fit all? 362
Androgen receptor expression and association with distant disease-free survival in triple negative breast cancer: Analysis of 263 patients treated with standard therapy for stage I-III disease 326
De-escalated therapy for HR+/HER2+ breast cancer patients with Ki67 response after 2 weeks letrozole: results of the PerELISA neoadjuvant study 324
Biomarkers for HER2-positive metastatic breast cancer: Beyond hormone receptors 314
Neoplastic Pericardial Effusion: A Monocentric Retrospective Study 312
Prognostic impact of proliferation for resected early stage ‘pure’ invasive lobular breast cancer: Cut-off analysis of Ki67 according to histology and clinical validation 304
Validation of Residual Proliferative Cancer Burden as a Predictor of Long-Term Outcome Following Neoadjuvant Chemotherapy in Patients with Hormone Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer 297
Early assessment of KRAS mutation in cfDNA correlates with risk of progression and death in advanced non-small-cell lung cancer 293
First-Line Osimertinib in Patients with EGFR-Mutant Advanced Non-Small Cell Lung Cancer: Outcome and Safety in the Real World: FLOWER Study 293
Prognostic significance of HER2-low status in HR-positive/HER2-negative advanced breast cancer treated with CDK4/6 inhibitors 290
Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors 290
Exceptional and Durable Responses to TDM-1 After Trastuzumab Failure for Breast Cancer Skin Metastases: Potential Implications of an Immunological Sanctuary 289
Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer 289
BMI is an independent prognostic factor for late outcome in patients diagnosed with early breast cancer: A landmark survival analysis 288
Patterns of Fertility Preservation and Pregnancy Outcome After Breast Cancer at a Large Comprehensive Cancer Center 287
Immune and gene-expression profiling in estrogen receptor low and negative early breast cancer 285
Epidemiology and clinical course of severe acute respiratory syndrome coronavirus 2 infection in cancer patients in the Veneto Oncology Network: The Rete Oncologica Veneta covID19 study 281
First Prospective Multicenter Italian Study on the Impact of the 21-Gene Recurrence Score in Adjuvant Clinical Decisions for Patients with ER Positive/HER2 Negative Breast Cancer 277
The role of immune microenvironment in small-cell lung cancer: Distribution of PD-L1 expression and prognostic role of FOXP3-positive tumour infiltrating lymphocytes 276
Longitudinal liquid biopsy predicts clinical benefit from immunotherapy in advanced non-small cell lung cancer 275
Clinical applications of radiomics and deep learning in breast and lung cancer: A narrative literature review on current evidence and future perspectives 275
A comprehensive profiling of the immune microenvironment of breast cancer brain metastases 275
Immunotherapy in small-cell lung cancer: From molecular promises to clinical challenges 275
Immune characterization of breast cancer metastases: Prognostic implications 274
Baseline levels and dynamic changes of cfDNA, tumor fraction and mutations to anticipate the clinical course of small cell lung cancer (SCLC) patients treated with first-line atezolizumab and chemotherapy: an hypothesis generating study (CATS/ML43257) 271
Integration of tumour infiltrating lymphocytes, programmed cell-death ligand-1, CD8 and FOXP3 in prognostic models for triple-negative breast cancer: Analysis of 244 stage I–III patients treated with standard therapy 271
Association of tumor-infiltrating lymphocytes with recurrence score in hormone receptor-positive/HER2-negative breast cancer: Analysis of four prospective studies 269
Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcome 269
Clinical features and treatment outcome of non-small cell lung cancer (NSCLC) patients with uncommon or complex epidermal growth factor receptor (EGFR) mutations 268
Impact of estrogen receptor levels on outcome in non-metastatic triple negative breast cancer patients treated with neoadjuvant/adjuvant chemotherapy 265
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation 262
Evolution of HER2-low expression from primary to recurrent breast cancer 260
Targeted next-generation sequencing identifies genomic abnormalities potentially driving the prognosis of early-stage invasive lobular breast carcinoma patients stratified according to a validated clinico-pathological model 259
Neoadjuvant Chemotherapy and Immunotherapy in Luminal B-like Breast Cancer: Results of the Phase II GIADA Trial 259
Clinical profile and mortality of Sars-Cov-2 infection in cancer patients across two pandemic time periods (Feb 2020-Sep 2020; Sep 2020-May 2021) in the Veneto Oncology Network: The ROVID study 257
Fertility Counseling Pattern over Time in Young Patients with Breast Cancer: A Retrospective Analysis at a Large Comprehensive Cancer Center 251
149P First-line (1L) osimertinib in EGFR mutant (mut) advanced non-small cell lung cancer (aNSCLC) patients (pts): Progression (PD) pattern and safety in the real-world (RW) 251
Beyond breast specific-Graded Prognostic Assessment in patients with brain metastases from breast cancer: treatment impact on outcome 249
Non-Small-Cell Lung Cancer: Real-World Cost Consequence Analysis 248
How the COVID-19 Pandemic Impacted on Integrated Care Pathways for Lung Cancer: The Parallel Experience of a COVID-Spared and a COVID-Dedicated Center 248
Real-world data on treatment outcomes in EGFR-mutant non-small-cell lung cancer patients receiving osimertinib in second or further lines 246
119P The role of circulating markers in predicting immune-related adverse events (irAEs) and their recurrence in advanced non-small cell lung cancer (aNSCLC) patients (pts) 244
HER2DX ERBB2 mRNA expression in advanced HER2-positive breast cancer treated with T-DM1 244
Gastric metastases of breast cancer: Histopathological and molecular characterization of a single Institution case series 243
miRNA Expression and HCC Occurrence in HCV Cirrhotic Patients Treated with Direct Acting Antivirals 242
A prognostic model based on nodal status and Ki 67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy 240
HER2-low-positive breast cancer: evolution from primary tumor to residual disease after neoadjuvant treatment 239
Olaparib for the treatment of breast cancer 239
Hormone receptors status: a strong determinant of the kinetics of brain metastases occurrence compared with HER2 status in breast cancer 238
Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1–T3, N0–N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study 237
Use of scalp cooling device to prevent alopecia for early breast cancer patients receiving chemotherapy: A prospective study 235
Detection of circulating immunosuppressive cytokines in malignant pleural mesothelioma patients for prognostic stratification 234
Longitudinal liquid biopsy anticipates hyperprogression and early death in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors 232
Tumor-Infiltrating Lymphocytes and Survival Outcomes in Early ERBB2-Positive Breast Cancer 231
Liquid biopsy and non-small cell lung cancer: are we looking at the tip of the iceberg? 230
18F-Fluoroestradiol Positron Emission Tomography In Breast Cancer Patients: Systematic Review Of The Literature &; Meta-Analysis 227
Metronomic Temozolomide in Heavily Pretreated Patients With Recurrent Isocitrate Dehydrogenase Wild-type Glioblastoma: A Large Real-Life Mono-Institutional Study 224
Osimertinib in Patients With Treatment-Naive EGFR-Mutant Non-small Cell Lung Cancer: Overall Survival, Post-progression Management and Budget Impact Analysis in Real-World 223
Therapeutic perspectives for brain metastases in non-oncogene addicted non-small cell lung cancer (NSCLC): Towards a less dismal future? 222
Lung cancer (LC) in HIV positive patients: Pathogenic features and implications for treatment 222
Gene-expression signatures to inform neoadjuvant treatment decision in HR+/HER2− breast cancer: Available evidence and clinical implications 221
Agreement between MRI and pathologic breast tumor size after neoadjuvant chemotherapy, and comparison with alternative tests: Individual patient data meta-analysis 220
Immune-Related Diarrhea and Colitis in Non-small Cell Lung Cancers: Impact of Multidisciplinary Management in a Real-World Setting 219
Circulating cytokines as predictors of response to immune checkpoint inhibitors (ICIs) in patients (pts) with melanoma (Mel) and non–small cell lung cancer (NSCLC) 218
External validation of Modified Breast Graded Prognostic Assessment for breast cancer patients with brain metastases: A multicentric European experience 218
51P Liver kinase B1 (LKB1) and phosphorylated AMP kinase (AMPK) expression in small cell lung cancer (SCLC): Association with prognosis and tumour immune microenvironment (TIME) features 218
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trial 217
Prognostic factors in phyllodes tumours of the breast: retrospective study on 166 consecutive cases 216
Characterization of Gut Microbiome Composition in Patients with Triple-Negative Breast Cancer Treated with Neoadjuvant Chemotherapy 215
Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer 214
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumab 212
Escalation and de-escalation in HER2 positive early breast cancer 211
Gastric Linitis Plastica and Peritoneal Carcinomatosis as First Manifestations of Occult Breast Carcinoma: A Case Report and Literature Review 211
Enhancing intracellular taxane delivery: current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer. 210
Achievements and unmet needs in the management of advanced ovarian cancer 210
The tumor microenvironment of primitive and metastatic breast cancer: Implications for novel therapeutic strategies 210
Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer 209
Development of two machine learning models to predict conversion from primary HER2-0 breast cancer to HER2-low metastases: a proof-of-concept study 207
A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy. 207
Diagnostic and prognostic impact of fluorine-18-fluorodeoxyglucose PET/CT in preoperative and postoperative setting of breast cancer patients 207
Plasma next-generation sequencing (NGS) in advanced non-small cell lung cancer (aNSCLC) patients (pts) treated with immune checkpoint inhibitors (ICIs): Impact of STK11 and TP53 mutations on outcome 207
Binary classification of copy number alteration profiles in liquid biopsy with potential clinical impact in advanced NSCLC 206
The immune system and hormone-receptor positive breast cancer: Is it really a dead end? 206
Gender minorities in breast cancer – Clinical trials enrollment disparities: Focus on male, transgender and gender diverse patients 205
HER2DX genomic test in HER2-positive/hormone receptor-positive breast cancer treated with neoadjuvant trastuzumab and pertuzumab: A correlative analysis from the PerELISA trial 204
GD2 expression in breast cancer 203
Potentialities of liquid biopsy in advanced non-small cell lung cancer (aNSCLC): Early evaluation of sentinel mutations in plasma and outcome of patients treated with immunotherapy 202
Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation 200
Sex-related differences in serum biomarker levels predict the activity and efficacy of immune checkpoint inhibitors in advanced melanoma and non-small cell lung cancer patients 200
Gene-expression assays to tailor adjuvant endocrine therapy for HR+/HER2- breast cancer 200
Multicenter Real-World Study on Effectiveness and Early Discontinuation Predictors in Patients With Non-small Cell Lung Cancer Receiving Nivolumab 200
Secondary prevention and treatment innovation of early stage non-small cell lung cancer: Impact on diagnostic-therapeutic pathway from a multidisciplinary perspective 199
HER2-enriched subtype and ERBB2 expression in HER2-positive breast cancer treated with dual HER2 blockade 199
Immunotherapy in SCLC: Exceptional Clinical Benefit and Abscopal Pneumonitis After Radiotherapy 199
Tumor Immune-Infiltrate Landscape After Chemo-Radiotherapy in a Case Series of Patients with Non-small Cell Lung Cancer: Pretreatment Predictors and Correlation With Outcome 198
Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials 198
SRC and PIM1 as potential co-targets to overcome resistance in MET deregulated non-small cell lung cancer 198
Totale 24.892
Salva come PNG Salva come JPEG
Categoria #
all - tutte 177.383
article - articoli 173.886
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 2.422
Totale 353.691
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20223.413 0 396 432 199 306 246 284 273 215 116 263 683
2022/20232.371 483 225 109 279 319 248 48 148 325 35 118 34
2023/20241.683 100 194 161 121 103 237 129 90 92 79 178 199
2024/20257.943 25 529 312 250 817 304 478 810 789 410 1.220 1.999
2025/202635.038 1.312 2.438 4.662 5.433 2.643 1.392 4.626 2.738 3.771 2.188 1.869 1.966
2026/20272.153 1.698 455 0 0 0 0 0 0 0 0 0 0
Totale 61.810